Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144293 · ClinicalTrials.gov registry record · Phase 2
Improving Physical Ability and Cellular Senescence Elimination in HIV
A Phase 2 study of HIV and Frailty, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT07144293 is a Phase 2 study of HIV and Frailty that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 80 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07144293, a Phase 2 study of HIV and Frailty, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Conditions Studied
Interventions
- DRUG Dasatinib
- DRUG Quercetin
- OTHER Placebo - Dasatinib
- OTHER Placebo - Quercetin
Study Locations (20)
California
- University of California, Los Angeles CARE Center CRS (Site ID: 601) - Los Angeles
- UCSD Antiviral Research Center CRS (Site ID: 701) - San Diego
- University of California, San Francisco HIV/AIDS CRS (Site ID: 801) - San Francisco
- Harbor University of California Los Angeles Center CRS (Site ID: 603) - Torrance
New York
- Weill Cornell Chelsea CRS (Site ID: 7804) - New York
- Columbia Physicians & Surgeons (P&S) CRS (Site ID: 30329) - New York
- Weill Cornell Uptown CRS (Site ID: 7803) - New York
- University of Rochester Adult HIV Therapeutic Strategies Network CRS (Site ID: 31787) - Rochester
Massachusetts
- Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) - Boston
- Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS (Site ID: 107) - Boston
North Carolina
- Chapel Hill CRS (Site ID: 3201) - Chapel Hill
- Greensboro CRS (Site ID: 3203) - Greensboro
Alabama
- Alabama CRS (Site ID: 31788) - Birmingham
Colorado
- University of Colorado Hospital CRS (Site ID: 6101) - Aurora
District of Columbia
- Whitman-Walker Institute, Inc. CRS (Site ID: 31791) - Washington D.C.
Georgia
- The Ponce de Leon Center CRS (Site ID: 5802) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-12-04 |
| Est. Completion | 2026-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07144293
The ClinicalTrials.gov registry entry for NCT07144293 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 303 other HIV trials with a reported enrollment target (82% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with HIV appearing as the primary indexed condition, and to 4 interventions - of which Dasatinib is the first listed.
NCT07144293 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07144293 about?
NCT07144293 is a clinical study titled "Improving Physical Ability and Cellular Senescence Elimination in HIV". This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living wit...
What is the current status of trial NCT07144293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-12-04. Estimated completion is 2026-11-29.
What conditions does trial NCT07144293 study?
This clinical trial studies the following conditions: HIV, Frailty, Aging Problems, Prefrail.
What interventions are being tested in trial NCT07144293?
The interventions under investigation include: Dasatinib (DRUG), Quercetin (DRUG), Placebo - Dasatinib (OTHER), Placebo - Quercetin (OTHER).
Who is sponsoring clinical trial NCT07144293?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144293 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV
RECRUITING · Phase 2
-
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
RECRUITING · Phase 2
-
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
RECRUITING · Phase 2
-
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
RECRUITING · Phase 2
-
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
RECRUITING · Phase 2
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.